Biotransformation of letrozole in rat liver microsomes: Effects of gender and tamoxifen

Journal of Pharmaceutical and Biomedical Analysis

Volumn 43, Issue 3, 2007, Pages 1078-1085

  Tao, X ^a   Piao, H ^b   Canney, D J ^a   Borenstein, M R ^a   Nnane, I P ^a  

^a TEMPLE UNIVERSITY SCHOOL OF PHARMACY   (United States)

^b YANBIAN UNIVERSITY   (China)

Author keywords

Gender; Letrozole; Liver microsomes; Metabolism; Tamoxifen

Indexed keywords

CGP 44 645; DRUG METABOLITE; LETROZOLE; TAMOXIFEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; DRUG STRUCTURE; DRUG TRANSFORMATION; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LIVER MICROSOME; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONTENT; SEX DIFFERENCE;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; BIOTRANSFORMATION; CALIBRATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG INTERACTIONS; FEMALE; MALE; MASS SPECTROMETRY; MICROSOMES, LIVER; NITRILES; RATS; RATS, SPRAGUE-DAWLEY; REPRODUCIBILITY OF RESULTS; SEX CHARACTERISTICS; SPECTROPHOTOMETRY, ULTRAVIOLET; TAMOXIFEN; TRIAZOLES;

EID: 33846612402     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2006.09.016     Document Type: Article

References (23)

1. Johnston S.R.D., and Dowsett M. Nat. Rev. Cancer 3 (2003) 821-831
2. Howell A., and Dowsett M. BMJ. 315 (1997) 863-866
3. Lake D.E., and Hudis C. Cancer Control 9 (2002) 490-498
4. Powles T.J., Hickish T., Kanis J.A., Tidy A., and Ashley S. J. Clin. Oncol. 14 (1996) 78-84
5. Love R.R., Barden H.S., Mazess R.B., Epstein S., and Chappell R.J. Arch. Int. Med. 154 (1994) 2585-2588
6. Early Breast Cancer Trialists' Collaborative Group, Lancet 351 (1998) 1451-1467.
7. S. Sellman, Nexus Magazine ejournal 5 (1998) (June-July). Avialable: http://www.nexusmagazine.com/backissue.html.
8. Jordon V.C. Ann. Rev. Pharmacol. Toxicol. 33 (1995) 195-211
9. Fisher B., Costantino J.P., and Wickerham D.L. J. Natl. Cancer Inst. 90 (1998) 1371-1388
10. DeFriend D.J., Anderson E., and Bell J. Br. J. Cancer 70 (1994) 204-211
11. Buzdar A.U. Clin. Cancer Res. 9 (2003) 468-472
12. Michaud L.B., and Buzdar A.U. Drug Saf. 21 (1999) 297-309
13. Schieweck K., Bhatnagar A.S., Batzi C., and Lang M. J. Steroid Biochem. Mol. Biol. 44 (1993) 633-636
14. Boroujerdi M. Pharmacokinetics: Principles and Applications (2002), McGraw-Hill, New York
15. Ickenstein L.M., Holsmer S.L., and Bandiera S.M. Pharm. Res. 21 (2004) 1631-1636
16. White I.N.H., Davies A., Smith L.L., Dawson D., and DeMatteis F. Biochem. Pharmacol. 45 (1993) 21-30
17. Zhao X.J., Jones D.R., Wang Y.H., Grimm S.W., and Hall S.D. Xenobiotica 32 (2002) 863-878
18. Bradford M. Anal. Biochem. 72 (1976) 248-254
19. Obach R.S., Baxter J.G., Liston T.E., Silber B.M., Jones B.C., MacIntyre F., Rance D.J., and Wastall P. J. Pharmacol. Exp. Ther. 283 (1997) 46-58
20. X. Tao, A.M. Brodie, I.P. Nnane, AAPS Annual Meeting, Salt lake city, UT, USA, Oct 26-30, 2003.
21. Lamb H.M., and Adkins J.C. Drugs 56 (1998) 1125-1140
22. Liu X.D., Xie L., and Zhong Y. Acta Pharmacol. Sin. 21 (2000) 680-684
23. Tao X., Brodie A.M.H., and Nnane I.P. Biopharm. Drug Dispos. 27 (2006) 335-344